Boehringer Ingelheim
Ingelheim am Rhein, Germany
Ingelheim am Rhein, Germany
Dr. Ulrich Scholz is a chemist by training. He studied Chemistry at the University of Hannover and as a DAAD scholar in Stanford University from 1991 to 1997 and pursued his PhD at the University of Hannover from where he graduated in 1999 from the research group of Prof. E. Winterfeldt on the biomimetic synthesis of bissteroidal pyrazines. He worked several years in the R&D department of Bayer AG in Leverkusen which transferred into Lanxess in 2003. In 2005 he joined Boehringer Ingelheim in Ingelheim as a principal scientist in process development. After a term in project management Ulrich was responsible for the technical launch of several APIs like Dabigatran and Linagliptin and in 2010 was expatriated to Shanghai in China to set up a local development group specialized on advanced chemical intermediates. From there, he moved on as a plant manager in Biberach, Germany for the galenics of capsulated controlled release formulations like Aggrenox and Pradaxa from 2013 to 2015. Then Ulrich took over the responsibility of a group to manage the launch and transfer of APIs for Boehringer. In 2017 he decided to switch companies to Bayer Pharmaceuticals in Wuppertal with the responsibility for the manufacture of the development NCEs of Bayer. Finally starting in 2020 Ulrich took over the responsibility of the Chemical Development Germany Department of his former company Boehringer including the role of the Chemical Development Network to coordinate the international activities of NCE API development.